rt-PA静脉溶栓联合灯盏细辛注射液治疗急性缺血性脑卒中的效果分析  

Effect analysis of RT-PA intravenous thrombolysis combined with Breviscap us injection in the treatment of acute ischemic stroke

作　　者：沈碧胜 李旷怡[1] 张英俭[1] 梁章荣[1] 陈景利[1] 洪丹东 宁驰 彭烈标[2] LI Kuangyi*;SHEN Bisheng;LI Kuangyi;ZHANG Yingjian;LINAG Zhangrong;CHEN Jingli;HONG Dandong;NING Chi;PENG Liebiao(Emergency Department,Foshan Hospital of T raditional Chinese Medicine,Foshan 528000;Department of Neurology,Foshan Hospital of T raditional Chinese Medicine,Foshan 528000)

机构地区：[1]佛山市中医院急诊科,广东佛山528000 [2]佛山市中医院神经内科,广东佛山528000

出　　处：《当代医药论丛》2022年第9期102-106,共5页

基　　金：广东省佛山市十四五高水平重点专科建设项目资助(项目编号:FSGSPZD135025);佛山市重点专科培育项目(编号:Fspy2-2015004);广东省佛山市科技局“佛山市脑卒中一体化综合救治平台的建设”(编号:2014AG10002);广东省佛山市科技局“急性缺血性脑卒中患者中医证型与B型钠尿肽的相关性研究”项目(编号:2017AB002651);广东省佛山市科技局医学类科技攻关项目,BNP联合D-D检测对CE型脑卒中患者的筛选价值研究(编号:2017AB002141)。

摘　　要：目的:探讨用重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓疗法联合灯盏细辛注射液治疗急性缺血性脑卒中的临床效果。方法:选取2018年1月至2019年6月佛山市中医院卒中中心收治的急性缺血性脑卒中患者84例(行rt-PA静脉溶栓治疗),对其临床资料进行回顾性研究。按是否使用灯盏细辛注射液进行治疗将其分为观察组(46例)及对照组(38例),比较两组患者的临床疗效、NIHSS评分、Barthel评分和不良反应的发生情况。结果:观察组患者治疗的总有效率明显高于对照组患者,P<0.05。治疗后,两组患者的NIHSS评分均较治疗前显著降低,P<0.05;观察组患者的NIHSS评分低于对照组患者,P<0.05。治疗后,两组患者的Barthel评分均较治疗前显著提高,P<0.05;观察组患者的Barthel评分高于对照组患者,P<0.05。治疗后,两组患者均未出现血压降低、头痛、过敏、胸闷、心悸等不良反应,其血尿常规指标、肝肾功能指标及电解质指标均无异常。结论:用rt-PA静脉溶栓疗法联合灯盏细辛注射液治疗急性缺血性脑卒中的临床效果显著,可有效地减轻患者的临床症状,改善其神经功能,提高其日常生活活动能力和生活质量,且安全性较高。Objective:To investigate the clinical effect of intravenous thrombolytic therapy with recombinant tissue plasminogen activator(RT-PA)combined with Breviscapus injection in the treatment of acute ischemic stroke.Methods:A total of 84 patients with acute ischemic stroke(receiving intravenous thrombolytic therapy with RT-PA)admitted to Stroke Center of Foshan Hospital of Traditional Chinese Medicine from January 2018 to June 2019 were selected to conduct a retrospective study on their clinical data.Patients were divided into observation group(46 cases)and control group(38 cases)according to whether breviscapus injection was used for treatment,and the clinical efficacy,NIHSS score,Barthel score and the occurrence of adverse reactions were compared between the two groups.Results:The total effective rate of observation group was significantly higher than control group,P<0.05.After treat ment,NIHSS scores of 2 groups were signif icantly lower than before treatment,P<0.05;NIHSS score of observation group was lower than that of control group,P<0.05.After treatment,the Barthel score of 2 groups was significantly higher than that before treatment,P<0.05;The Barthel score of observation group was higher than that of control group,P<0.05.After treatment,there were no adverse reactions such as decreased blood pressure,headache,allergy,chest tightness and palpitations in 2 groups,and no abnormalities in routine indexes of hematuria,liver and kidney function and electrolyte indexes.Conclusion:RT-PA intravenous thrombolytic therapy combined with Breviscapus injection in the treatment of acute ischemic stroke has a significant clinical effect,which can effectively reduce the clinical symptoms of patients,improve their neurological function,improve their ability of daily liv ing activities and quality of life,and has a high safety.

关 键 词：急性缺血性脑卒中 RT-PA静脉溶栓 灯盏细辛注射液 NIHSS评分 Barthel评分 

分 类 号：R743[医药卫生—神经病学与精神病学]